AzTrials
AzTrials

Personality DisordersNCT06804369

Benchmarking and Change Mechanisms in Personality Disorder Treatment

An observational study of Personality Disorders, run by KU Leuven at 1 site in Belgium.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Personality disorders (PDs) are severe mental disorders characterized by pathological personality traits as well as problems in identity and interpersonal relationships (American Psychiatric Association, 2013). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Personality Disorders
What is being tested?
Intensive psychodynamic therapy (PDT)
How many people
91 participants
Where
1 siteBelgium
Study dates
17 Apr 2023to 17 Apr 2028
How long will I take part?
2 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Participants will be consecutively admitted patients to the Klipp treatment unit at the University Psychiatric Center (UPC) KU Leuven, Campus Kortenberg (Belgium) which provides specialized treatment for PDs, starting from April 17 2023 until the target sample size of N = 110 is reached.

Who may be able to join

  • Individuals (male, female, non-binary or other) older than 18 years
  • Meeting criteria for personality disorder as assessed by a psychiatrist and confirmed with the PID-5 and LFPS self-report scales
  • Sufficient mastery of the Dutch language to follow treatment and complete questionnaires
  • Agreeing to participate in the study following informed consent procedure

Who cannot join

  • Substance abuse that would interfere with the ability to adhere to the treatment
  • Acute psychotic symptoms as assessed by a psychiatrist

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • University Psychiatric Center KU Leuven

    Kortenberg, Vlaams-Brabant, 3070

Other trials in Belgium

About this study

Official title: Benchmarking and Mechanisms of Change During Intensive Psychodynamic Therapy for Personality Disorders: A Naturalistic Process-Outcome Study

Personality disorders (PDs) are severe mental disorders characterized by pathological personality traits as well as problems in identity and interpersonal relationships (American Psychiatric Association, 2013). Several effective psychotherapies for PDs have been developed in the past decades, however, two important questions regarding PD treatment have not been sufficiently addressed: (1) how effective are PD treatments outside of the controlled settings of randomized controlled trials (RCTs); (2) are the effects of PDT clinically meaningful; and (3) what are the core processes that produce change in PD treatment? The present observational study aims to address these research gaps by (1) comparing the effects of intensive psychodynamic therapy (PDT) for PDs in a naturalistic setting to benchmarks found in RCTs; (2) analyzing which proportion of patients achieves clinically meaningful change and (3) investigating whether outcomes in intensive PDT are associated with a number of theoretically expected mechanisms of change.

Read the detailed description

Personality disorders (PDs) are characterized by problems with identity and interpersonal relationships and the presence of pathological personality traits (American Psychiatric Association, 2013). Personality disorders are prevalent, affecting about 6 - 9.5% of people in the community (Winsper et al., 2020) and result in increased morbidity and mortality (Grant et al., 2008). Several effective psychotherapies for PDs have been developed in the past decades. Meta-analyses of randomized controlled trials (RCTs) demonstrate that psychotherapy for PDs is efficacious and that different treatment models for PDs produce comparable effects (Budge et al., 2013; Cristea et al., 2017; Storebø et al., 2020). However, two important questions remain: (1) how effective are PD treatments outside of the controlled settings of RCTs and (2) what are the core processes that produce change in PD treatment?

First, evidence on the efficacy of PD treatment in controlled circumstances (RCTs) does not necessarily translate directly to the effectiveness of treatment as it is actually being delivered in routine clinical practice. Several studies have demonstrated the effectiveness of PD treatment in naturalistic settings (Gregory \& Sachdeva, 2016; Lowyck et al., 2015), however, these studies have not systematically compared their effects with those from published RCTs (Malmivaara, 2015). Therefore, the primary aim of the present study is to compare the effects of intensive psychodynamic therapy (PDT) for PDs in a naturalistic setting to benchmarks found in RCTs. Specifically, the primary objective of this study is to investigate the non-inferiority with a margin of d = 0.2 of intensive PDT for PDs as it is delivered in routine clinical practice compared to benchmarks from published RCTs of PDT for PDs. The benchmarks are created by meta-analytically aggregating the effects found in well-conducted RCTs following the methods proposed by Minami et al. (2008). The primary outcome is change in general symptom severity as measured by the global severity index (GSI) on the Brief Symptom Inventory (BSI) from start to end of treatment (approximately 8 months after the start of treatment).

Second, the effectiveness of intensive PDT for PD in terms of pre-post effect sizes will be investigated as well as clinical significant change (CSC) and deterioration using reliable change indices (Jacobson \& Truax, 1991) from baseline to treatment termination as well as 6-month and 1- and 2-year follow up, on the following outcomes: psychological distress (Brief Symptom Inventory; BSI), borderline personality disorder symptoms (Personality Assessment Inventory for BPD; PAI-BOR); personality functioning (Level of Personality Functioning Scale; LPFS), interpersonal functioning (Inventory of Interpersonal Problems; IIP), post-traumatic stress (Post-traumatic stress disorder Checklist for DSM-5; PCL-5), resilience (Connor-Davidson Resilience Scale; CD-RISC) and quality of life (EQ-5D).

Third, in order to ensure that existing therapies for PDs focus on the actual core processes that produce change, more research is needed to address why and how treatment for PD works (Kramer, 2018). The present study's secondary aim is therefore to investigate whether outcomes in intensive PDT are associated with a number of theoretically expected mechanisms of change. It has been argued that successful treatment for PDs fosters epistemic trust, that is, trust in communicated knowledge, which in turn allows for the re-emergence of learning from benign social influences, increasing resilience and reducing PD symptoms (Fonagy et al., 2019). Epistemic trust is thus theoretically considered a core change mechanism in all effective treatments for PD, however, no study to date has empirically tested this. The secondary objective of the present study is to investigate whether trajectories of change in epistemic trust, mistrust and credulity across treatment (as measured using the Epistemic Trust, Mistrust and Credulity Questionnaire, ETMCQ) are associated with the trajectories of symptom change across treatment (as measured using the Brief Symptom Inventory, BSI, and the Personality Assessment Inventory for borderline PD, PAI-BOR) using parallel process growth curve modeling (MacCallum et al., 1997). Mentalizing and therapeutic alliance are investigated as secondary change mechanisms to assess the relative importance of epistemic trust as a change mechanism in the treatment of PD.

This observational clinical study aims to recruit N = 110 PD patients consecutively admitted to a treatment unit that specializes in intensive PDT for PDs (Klipp, UPC KU Leuven, Belgium). Patients follow one of three programs that differ in treatment intensity: (1) inpatient treatment program (5 days a week), (2) day treatment program (4 days a week), and (3) a part-time outpatient treatment program of two half days per week. Patients attend one of these programs and stay in the program for at least 6 months (with an average duration of 8 months). For pragmatic reasons, patients are not randomized across the treatment programs. Sensitivity analyses will be performed and if appropriate given our sample size, differences in baseline characteristics and treatment effects between the programs will be investigated.

Self-report questionnaires on personality functioning, symptoms, resilience, quality of life, epistemic trust, mentalizing and the therapeutic alliance are filled out via REDCAP, an online platform, at baseline, after 3 and 6 months of treatment, at discharge, and 6-months and at 1 and 2 year follow-up. Automated invitations and reminders are sent via e-mail. Automated scoring and codebooks are implemented via REDCAP. A designated study data manager follows up participant progress and provides support. The data manager additionally logs drop-out including the reason for treatment termination and the occurrence of the following serious adverse events (SAE's): suicide attempt, life-threatening self-harm, patient death, serious injury or medical disease that requires hospitalization.

References:

American Psychiatric Association. (2013). Diagnositic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing. https://doi.org/10.1176/appi.books.9780890425596.744053

Budge, S. L., Moore, J. T., Del Re, A. C., Wampold, B. E., Baardseth, T. P., \& Nienhuis, J. B. (2013). The effectiveness of evidence-based treatments for personality disorders when comparing treatment-as-usual and bona fide treatments. Clin Psychol Rev, 33(8), 1057-1066. https://doi.org/10.1016/j.cpr.2013.08.003

Cristea, I. A., Gentili, C., Cotet, C. D., Palomba, D., Barbui, C., \& Cuijpers, P. (2017). Efficacy of Psychotherapies for Borderline Personality Disorder: A Systematic Review and Meta-analysis. Jama Psychiatry, 74(4), 319-328. https://doi.org/10.1001/jamapsychiatry.2016.4287

Fonagy, P., Luyten, P., Allison, E., \& Campbell, C. (2019). Mentalizing, Epistemic Trust and the Phenomenology of Psychotherapy. Psychopathology. https://doi.org/10.1159/000501526

Grant, B. F., Chou, S. P., Goldstein, R. B., Huang, B., Stinson, F. S., Saha, T. D., Smith, S. M., Dawson, D. A., Pulay, A. J., Pickering, R. P., \& Ruan, W. J. (2008). Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 69(4), 533-545. https://doi.org/10.4088/jcp.v69n0404

Gregory, R. J., \& Sachdeva, S. (2016). Naturalistic Outcomes of Evidence-Based Therapies for Borderline Personality Disorder at a Medical University Clinic. Am J Psychother, 70(2), 167-184. https://doi.org/10.1176/appi.psychotherapy.2016.70.2.167

Jacobson, N. S., \& Truax, P. (1991). Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol, 59(1), 12-19. https://doi.org/10.1037//0022-006x.59.1.12

Kramer, U. (2018). Mechanisms of Change in Treatments of Personality Disorders: Introduction to the Special Section. Journal of Personality Disorders, 32(Suppl), 1-11. https://doi.org/10.1521/pedi.2018.32.supp.1

Lowyck, B., Vermote, R., Verhaest, Y., Vandeneede, B., Wampers, M., Luyten, P., \& Wampers, M. (2015). Hospitalization-based psychodynamic treatment for personality disorders: A five-year follow-up. Psychoanalytic Psychology, 32, 381-402. https://doi.org/10.1037/a0038959

MacCallum, R. C., Kim, C., Malarkey, W. B., \& Kiecolt-Glaser, J. K. (1997). Studying multivariate change using multilevel models and latent curve models. Multivariate Behavioral Research, 32, 215-253. https://doi.org/10.1207/s15327906mbr3203

Malmivaara, A. (2015). Benchmarking Controlled Trial--a novel concept covering all observational effectiveness studies. Ann Med, 47(4), 332-340. https://doi.org/10.3109/07853890.2015.1027255

Storebø, O. J., Stoffers-Winterling, J. M., Völlm, B. A., Kongerslev, M. T., Mattivi, J. T., Jørgensen, M. S., Faltinsen, E., Todorovac, A., Sales, C. P., Callesen, H. E., Lieb, K., \& Simonsen, E. (2020). Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev, 5(5), Cd012955. https://doi.org/10.1002/14651858.CD012955.pub2

Winsper, C., Bilgin, A., Thompson, A., Marwaha, S., Chanen, A. M., Singh, S. P., Wang, A., \& Furtado, V. (2020). The prevalence of personality disorders in the community: a global systematic review and meta-analysis. The British Journal of Psychiatry, 216(2), 69-78. https://doi.org/10.1192/bjp.2019.166

Being tested
Intensive psychodynamic therapy (PDT)
Keywords
personality disorders, change mechanisms, benchmarking, epistemic trust, mentalizing, resilience, psychodynamic therapy
Medical subject headings
Personality Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intensive psychodynamic therapy (PDT)Behavioural

    Also called Psychodynamic Psychotherapy

    The KLIPP treatment unit (UPC KU Leuven, campus Kortenberg) provides intensive psychodynamic treatment (PDT) for patients with different types of PDs. There are three different programs that differ in treatment intensity: (1) inpatient treatment program (5 days a week), (2) day treatment program (4 days a week), and (3) a part-time outpatient treatment program of two half days per week. Patients attend one of these programs and stay in the program for at least 6 months (with an average duration of 8 months). The programs include individual and group psychodynamic psychotherapy as well as art, music and psychomotor therapy.

Study groups in NCT06804369
Study groupRoleWhat they receive
Personality Disorder PatientsAll patients consecutively admitted to the KLIPP treatment unit (UPC KU Leuven, Belgium) until the target sample size (N = 110) is reached. All patients have been referred to this specialized treatment because of prominent personality disorder pathology and undergo multidisciplinary assessment by a psychiatrist, clinical psychologist and social worker.
Receives: Behavioral: Intensive psychodynamic therapy (PDT)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in General Psychological Symptoms

    Self-reported severity of general psychological symptoms as assessed using the Brief Symptom Inventory (BSI; Derogatis \& Melisaratos, 1983).

    Measured: From baseline to treatment termination (on average 9 months after the start of treatment)

Secondary outcomes (7)
  1. Changes in Borderline Personality Disorder Symptom Severity

    Self-reported severity of borderline symptomatology and assessed via the Personality Assessment Inventory - Borderline subscale (PAI-BOR; Distel et al. (2009)).

    Measured: From baseline to treatment termination (on average 9 months after the start of treatment), and at 6-month, and one- and two-year follow-up

  2. Changes in General Psychological Symptoms

    Self-reported severity of general psychological symptoms as assessed using the Brief Symptom Inventory (BSI; Derogatis \& Melisaratos, 1983).

    Measured: From baseline to 6-month, and one- and two-year follow-up

  3. Changes in Personality Functioning

    Self-reported severity of personality pathology, as measured using the Level of Personality Functioning Scale (LPFS; Hutsebaut et al., 2015)

    Measured: From baseline to treatment termination (on average 9 months after the start of treatment), and 6-month, and one- and two-year follow-up

  4. Changes in Interpersonal Problems

    Self-reported severity of interpersonal problems assessed with the Inventory of Interpersonal Problems (IIP; Barkham et al., 1996)

    Measured: From baseline to treatment termination (on average 9 months after the start of treatment), and 6-month, and one- and two-year follow-up

  5. Changes in Symptoms of Post-traumatic Stress

    Self-reported severity of symptoms of Post-traumatic Stress Disorder (PTSD), assessed with the PTSD Checklist for DSM-5 (PCL-5; Van Praag et al., 2020)

    Measured: From baseline to treatment termination (on average 9 months after the start of treatment), and 6-month, and one- and two-year follow-up

  6. Changes in Resilience

    Self-reported resilience to deal with life stressors, measured with the Connor-Davidson Resilience Scale (CD-RISC; Connor \& Davidson, 2003)

    Measured: From baseline to treatment termination (on average 9 months after the start of treatment), and 6-month, and one- and two-year follow-up

  7. Changes in Quality of Life

    Self-reported health-related quality of life as assessed with the EuroQol Quality of life 5 dimensions (EQ-5D; Herdman et al., 2011)

    Measured: From baseline to treatment termination (on average 9 months after the start of treatment), and 6-month, and one- and two-year follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Feb 2025
  2. Study start17 Apr 2023
  3. Primary completion17 Apr 2026 (estimated)
  4. Study completion17 Apr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
91 participants (actual)
Target duration
2 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT06804369
Sponsor's protocol ID
S67356
Status last verified
Dec 2025
First submitted
21 Jan 2025
Last updated
10 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: IPD will be made available upon reasonable request from other researchers, including a research plan of how they plan to use the data.

Questions about this trial

What is this clinical trial studying?

An observational study of Personality Disorders, run by KU Leuven at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 10 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in General Psychological Symptoms (time frame: From baseline to treatment termination (on average 9 months after the start of treatment)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in